Next Article in Journal
Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists
Previous Article in Journal
Retrospective Analysis of the Effect of CAPOX and mFOLFOX6 Dose Intensity on Survival in Colorectal Patients in the Adjuvant Setting
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Open AccessArticle

Approach to Biomarker Testing: Perspectives from Various Specialties

1
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2
Juravinski Cancer Centre, Hamilton, ON, Canada
3
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
4
CONVERGE Advertising (CARE Staff), Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(3), 178-183; https://doi.org/10.3747/co.23.3019
Received: 9 March 2016 / Revised: 14 April 2016 / Accepted: 9 May 2016 / Published: 1 June 2016
Background: Despite its importance for patient outcomes, biomarker testing for lung cancer is not uniformly integrated into the Canadian health care system. To better understand current practice patterns for lung cancer biomarker testing, we assessed physician perspectives by specialty and region. Methods: A national survey of Canadian lung cancer specialists was conducted to understand their perspectives on biomarker testing in lung cancer. The 11-item survey assessed the current practice and challenges of testing. The survey was sent to 375 specialists. Results: The overall response rate for the survey was 36%. Nearly all specialists reported that knowing tumour genotyping results affects patient outcome and influences the treatment decision. Medical oncologists most commonly initiated molecular testing; however, most respondents suggested a shared model involving medical oncologists and pathologists. More than half of all responding specialists had the perception that fewer than 25% of test results are available for first-line treatment decisions. Identified barriers to routine testing for all lung cancer patients included cost, lack of funding, tissue availability, and sample quality. Conclusions: There was clear agreement that biomarker testing is important in determining appropriate treatment for patients. There is a need for general consensus on who should initiate molecular testing. Clear clinical guidance for pathologists has to be established for molecular testing, including defining the population to be tested, the timing of testing, and the tests to be performed. Testing could be facilitated by including more information on diagnostic sample requisitions, such as clinical suspicion of primary lung cancer, cancer history, and other samples already collected.
Keywords: advanced lung cancer; biomarker testing; testing patterns; testing barriers advanced lung cancer; biomarker testing; testing patterns; testing barriers
MDPI and ACS Style

Sung, M.R.; Ellis, P.M.; Verma, S.; Duncan, E.; Leighl, N.B. Approach to Biomarker Testing: Perspectives from Various Specialties. Curr. Oncol. 2016, 23, 178-183. https://doi.org/10.3747/co.23.3019

AMA Style

Sung MR, Ellis PM, Verma S, Duncan E, Leighl NB. Approach to Biomarker Testing: Perspectives from Various Specialties. Current Oncology. 2016; 23(3):178-183. https://doi.org/10.3747/co.23.3019

Chicago/Turabian Style

Sung, M.R.; Ellis, P.M.; Verma, S.; Duncan, E.; Leighl, N.B. 2016. "Approach to Biomarker Testing: Perspectives from Various Specialties" Curr. Oncol. 23, no. 3: 178-183. https://doi.org/10.3747/co.23.3019

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop